| Major Class                     | Subclass                           | Mechanism of Action                | Example Agents                                | Main Target Systems / Infections                              | Key Notes                                   |
| ------------------------------- | ---------------------------------- | ---------------------------------- | --------------------------------------------- | ------------------------------------------------------------- | ------------------------------------------- |
| **Beta-Lactams**                | **Natural Penicillins**            | Inhibit cell wall synthesis        | Penicillin G, Penicillin V                    | Skin, respiratory (streptococcal), CNS (meningitis), syphilis | Narrow Gram+ coverage                       |
|                                 | **Aminopenicillins**               | Inhibit cell wall synthesis        | Amoxicillin, Ampicillin                       | Respiratory, ENT, urinary, GI                                 | Add clavulanate for β-lactamase producers   |
|                                 | **Penicillin + Inhibitor**         | Inhibit cell wall synthesis        | Amoxicillin/Clavulanate, Ampicillin/Sulbactam | Mixed infections (respiratory, intra-abdominal, skin)         | Broad Gram± and anaerobes                   |
|                                 | **Antistaphylococcal Penicillins** | Inhibit cell wall synthesis        | Flucloxacillin, Oxacillin                     | Skin, soft tissue, bone, MSSA                                 | No MRSA coverage                            |
|                                 | **Antipseudomonal Penicillins**    | Inhibit cell wall synthesis        | Piperacillin/Tazobactam                       | Hospital-acquired pneumonia, sepsis, intra-abdominal          | Covers Pseudomonas, broad spectrum          |
| **Cephalosporins**              | **1st Generation**                 | Inhibit cell wall synthesis        | Cefazolin, Cephalexin                         | Skin, bone, surgical prophylaxis                              | Strong Gram+                                |
|                                 | **2nd Generation**                 | Inhibit cell wall synthesis        | Cefuroxime, Cefaclor                          | Respiratory, ENT, urinary                                     | Broader Gram– than 1st gen                  |
|                                 | **3rd Generation**                 | Inhibit cell wall synthesis        | Ceftriaxone, Cefotaxime, Ceftazidime          | CNS (meningitis), sepsis, pneumonia                           | Ceftazidime covers Pseudomonas              |
|                                 | **4th Generation**                 | Inhibit cell wall synthesis        | Cefepime                                      | Hospital pneumonia, sepsis                                    | Stable against many β-lactamases            |
|                                 | **5th Generation**                 | Inhibit cell wall synthesis        | Ceftaroline, Ceftobiprole                     | MRSA, pneumonia, skin infections                              | Covers MRSA and Gram–                       |
| **Monobactams**                 | —                                  | Inhibit cell wall synthesis        | Aztreonam                                     | Gram– infections, UTI, respiratory                            | Safe for penicillin allergy                 |
| **Carbapenems**                 | —                                  | Inhibit cell wall synthesis        | Meropenem, Imipenem, Ertapenem                | Sepsis, intra-abdominal, MDR infections                       | Very broad, last-line hospital use          |
| **Glycopeptides**               | —                                  | Inhibit cell wall synthesis        | Vancomycin, Teicoplanin                       | MRSA, enterococcal, endocarditis                              | Gram+ only, renal toxicity risk             |
| **Lipoglycopeptides**           | —                                  | Inhibit cell wall synthesis        | Dalbavancin, Oritavancin                      | Skin, MRSA, long-term outpatient therapy                      | Long half-life                              |
| **Fosfomycin**                  | —                                  | Inhibit cell wall synthesis        | Fosfomycin                                    | Urinary tract infections                                      | Single-dose therapy, E. coli active         |
| **Polymyxins**                  | —                                  | Disrupt cell membrane              | Colistin, Polymyxin B                         | MDR Gram–, ventilator pneumonia                               | Nephrotoxic, last resort                    |
| **Daptomycin**                  | —                                  | Disrupt cell membrane              | Daptomycin                                    | MRSA, VRE bacteremia, endocarditis                            | Inactive in pneumonia                       |
| **Tetracyclines**               | —                                  | Inhibit protein synthesis (30S)    | Doxycycline, Minocycline                      | Respiratory (atypicals), skin, tick-borne, STI                | Avoid in pregnancy/children                 |
| **Glycylcyclines**              | —                                  | Inhibit protein synthesis (30S)    | Tigecycline                                   | Intra-abdominal, skin, polymicrobial                          | Broad spectrum, bacteriostatic              |
| **Aminoglycosides**             | —                                  | Inhibit protein synthesis (30S)    | Gentamicin, Amikacin, Tobramycin              | Sepsis, endocarditis, UTI                                     | Synergy with β-lactams                      |
| **Macrolides**                  | —                                  | Inhibit protein synthesis (50S)    | Azithromycin, Clarithromycin, Erythromycin    | Respiratory (atypicals), STI, skin                            | High resistance among Streptococci          |
| **Ketolides**                   | —                                  | Inhibit protein synthesis (50S)    | Telithromycin                                 | Respiratory infections                                        | Rarely used (hepatotoxicity)                |
| **Oxazolidinones**              | —                                  | Inhibit protein synthesis (50S)    | Linezolid, Tedizolid                          | MRSA, VRE, pneumonia                                          | Good oral bioavailability                   |
| **Lincosamides**                | —                                  | Inhibit protein synthesis (50S)    | Clindamycin                                   | Anaerobic, dental, skin infections                            | Risk of C. difficile colitis                |
| **Streptogramins**              | —                                  | Inhibit protein synthesis (50S)    | Quinupristin/Dalfopristin                     | VRE (E. faecium), skin                                        | Limited use                                 |
| **Fluoroquinolones**            | **2nd Gen**                        | Inhibit DNA gyrase / topoisomerase | Ciprofloxacin, Ofloxacin                      | Urinary, GI, Gram–                                            | Not for simple infections due to resistance |
|                                 | **3rd/4th Gen**                    | Inhibit DNA gyrase / topoisomerase | Levofloxacin, Moxifloxacin                    | Respiratory, skin, soft tissue                                | QT prolongation risk                        |
| **Rifamycins**                  | —                                  | Inhibit RNA polymerase             | Rifampicin, Rifaximin                         | Tuberculosis, traveler’s diarrhea                             | Always combine for TB                       |
| **Sulfonamides & Trimethoprim** | —                                  | Inhibit folate synthesis           | Cotrimoxazole (TMP-SMX)                       | Pneumocystis, UTI, MRSA skin                                  | High resistance in E. coli                  |
| **Nitrofurans**                 | —                                  | DNA damage                         | Nitrofurantoin                                | Uncomplicated cystitis                                        | Active vs. E. coli, avoid in renal failure  |
| **Metronidazole**               | —                                  | DNA damage (anaerobes)             | Metronidazole                                 | Intra-abdominal, gynecologic, dental                          | Avoid alcohol, covers anaerobes & protozoa  |
